NO993979L - FremgangsmÕte for Õ forhindre og forsinke starten pÕ Alzheimer's sykdom og sammensetning derfor - Google Patents

FremgangsmÕte for Õ forhindre og forsinke starten pÕ Alzheimer's sykdom og sammensetning derfor

Info

Publication number
NO993979L
NO993979L NO993979A NO993979A NO993979L NO 993979 L NO993979 L NO 993979L NO 993979 A NO993979 A NO 993979A NO 993979 A NO993979 A NO 993979A NO 993979 L NO993979 L NO 993979L
Authority
NO
Norway
Prior art keywords
alzheimer
onset
disease
composition
procedures
Prior art date
Application number
NO993979A
Other languages
English (en)
Norwegian (no)
Other versions
NO993979D0 (no
Inventor
Egon Novak
Original Assignee
Forbes Medi Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forbes Medi Tech Inc filed Critical Forbes Medi Tech Inc
Publication of NO993979D0 publication Critical patent/NO993979D0/no
Publication of NO993979L publication Critical patent/NO993979L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO993979A 1997-12-18 1999-08-18 FremgangsmÕte for Õ forhindre og forsinke starten pÕ Alzheimer's sykdom og sammensetning derfor NO993979L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/993,901 US5985936A (en) 1997-12-18 1997-12-18 Method of preventing and delaying onset of Alzheimer's disease and composition therefor
PCT/CA1998/001147 WO1999032097A2 (en) 1997-12-18 1998-12-18 Phytosterol composition for preventing alzheimer's disease

Publications (2)

Publication Number Publication Date
NO993979D0 NO993979D0 (no) 1999-08-18
NO993979L true NO993979L (no) 1999-10-13

Family

ID=25540052

Family Applications (1)

Application Number Title Priority Date Filing Date
NO993979A NO993979L (no) 1997-12-18 1999-08-18 FremgangsmÕte for Õ forhindre og forsinke starten pÕ Alzheimer's sykdom og sammensetning derfor

Country Status (18)

Country Link
US (1) US5985936A (xx)
EP (1) EP0967982A2 (xx)
CN (1) CN1252724A (xx)
AU (1) AU1656099A (xx)
BG (1) BG103740A (xx)
BR (1) BR9807577A (xx)
CA (1) CA2281710A1 (xx)
EE (1) EE9900354A (xx)
GE (1) GEP20022783B (xx)
HU (1) HUP0100737A3 (xx)
LT (1) LT4801B (xx)
LV (1) LV12438B (xx)
MD (1) MD1920F2 (xx)
NO (1) NO993979L (xx)
PL (1) PL335421A1 (xx)
RU (1) RU2173151C2 (xx)
SK (1) SK112999A3 (xx)
WO (1) WO1999032097A2 (xx)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060141036A1 (en) * 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
US20020107173A1 (en) * 1999-11-04 2002-08-08 Lawrence Friedhoff Method of treating amyloid beta precursor disorders
NZ518822A (en) * 1999-11-04 2004-12-24 Andrx Corp Treating a mammal with an APP processing disorder such as Alzheimer's Disease and Down's Syndrome by administering at least one HMG-CoA reductase inhibitor
ATE439051T1 (de) 2000-04-14 2009-08-15 Mars Inc Zusammensetzungen und methoden zur verbesserung der vaskulären gesundheit
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US20030013692A1 (en) * 2001-01-19 2003-01-16 Gullans Steven R. Methods of treating neurological disorders
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
AU2002237847A1 (en) * 2001-02-12 2002-08-28 Akzo Nobel N.V Methods for improving the treatment of major depression by genotyping for the gene for apolipoproteine e4
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
DE10154221A1 (de) * 2001-11-07 2003-05-15 Max Delbrueck Centrum Mittel zur Behandlung von Läsionen des Nervensystems
FR2848452B1 (fr) * 2002-12-12 2007-04-06 Aventis Pharma Sa Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
ATE418551T1 (de) 2003-03-07 2009-01-15 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
DE602004016123D1 (de) 2003-03-07 2008-10-09 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
CA2517573C (en) * 2003-03-07 2011-12-06 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
GB0513881D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
GB0329667D0 (en) * 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
US20080182801A1 (en) 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
US20050277129A1 (en) * 2004-01-22 2005-12-15 Genaissance Pharmaceuticals APOE genetic markers associated with age of onset of Alzheimer's disease
CN101291683B (zh) * 2004-11-24 2011-08-17 纽普罗研究有限公司 治疗疾病的方法和组合物
GB0512726D0 (en) * 2005-06-22 2005-07-27 Btg Int Ltd Multiple sclerosis therapy and diagnosis
GB0513888D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
GB0513883D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Diagnosis of Atherosclerosis
WO2009118187A1 (en) * 2008-03-27 2009-10-01 Evotec Neurosciences Gmbh Methods for treating disorders using nmda nr2b-subtype selective antagonist
WO2010104375A1 (en) 2009-03-12 2010-09-16 N.V. Nutricia Stigmasterol for the treatment of alzheimer's disease
US10383886B2 (en) 2010-01-11 2019-08-20 Phoenix Biotechnology, Inc. Method of treating neurological conditions with oleandrin
US10307450B2 (en) 2010-01-11 2019-06-04 Phoenix Biotechnology, Inc. Method of treating neurological conditions with extract of Nerium species or Thevetia species
US9011937B2 (en) 2010-11-22 2015-04-21 Phoenix Biotechnology, Inc. Method of treating neurological conditions with extract of Nerium species or Thevetia species
US9376481B2 (en) 2011-04-26 2016-06-28 The Regents Of The University Of California Methods of promoting CNS neuronal repair by inhibiting LRP-1
CN102813659A (zh) * 2012-08-21 2012-12-12 贵阳中医学院 20α-二甲胺基- 2α-羟基-3β-惕洛酰胺基-5α-孕甾烷的用途
WO2015123618A1 (en) * 2014-02-14 2015-08-20 Arizona Board Of Regents For The University Of Arizona Method for increasing bcl2 gene expression
US10702567B2 (en) 2016-09-14 2020-07-07 Phoenix Biotechnology, Inc. Method and compositions for treating viral infection
US10596186B2 (en) 2016-09-14 2020-03-24 Phoenix Biotechnology, Inc. Method and compositions for treating viral infections
US11331291B2 (en) 2017-09-14 2022-05-17 Phoenix Biotechnology, Inc. Method of and improved composition for treating triterpene-responsive conditions, diseases or disorders
CA3075023A1 (en) 2017-09-14 2019-03-21 Phoenix Biotechnology, Inc. Method and improved neuroprotective composition for treating neurological conditions
EP3842039A1 (en) * 2019-12-24 2021-06-30 Folium Biosciences Europe B.V. Food supplement comprising cannbinoids and phytosterols for alzheimer
EP4081198A1 (en) 2019-12-24 2022-11-02 Folium Biosciences Europe B.V. Food supplement for alzheimer
US11806359B2 (en) 2020-03-31 2023-11-07 Phoenix Biotechnology, Inc. Method and compositions for treating Coronavirus infection

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1203515B (it) * 1987-02-26 1989-02-15 Indena Spa Complessi di saponine con fosfolipidi e composizioni farmaceutiche e cosmetiche che li contengono
AU6274394A (en) * 1993-02-23 1994-09-14 Pharmakon Usa, Inc. Therapeutic herbal composition
US5589182A (en) * 1993-12-06 1996-12-31 Tashiro; Renki Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression
HUT77522A (hu) * 1994-09-29 1998-05-28 The University Of British Columbia Fitoszterin-kompozíciók és eljárás azok kinyerésére pulpaszappanokból
CN1179903A (zh) * 1996-10-09 1998-04-29 李辉 营养丝米粉
WO1998051302A1 (en) * 1997-05-15 1998-11-19 University Of Washington Composition and methods for treating alzheimer's disease and other amyloidoses

Also Published As

Publication number Publication date
RU2173151C2 (ru) 2001-09-10
SK112999A3 (en) 2001-11-06
AU1656099A (en) 1999-07-12
US5985936A (en) 1999-11-16
MD1920F2 (ro) 2002-05-31
EE9900354A (et) 2000-02-15
NO993979D0 (no) 1999-08-18
CN1252724A (zh) 2000-05-10
PL335421A1 (en) 2000-04-25
EP0967982A2 (en) 2000-01-05
WO1999032097A2 (en) 1999-07-01
GEP20022783B (en) 2002-09-25
WO1999032097A3 (en) 1999-09-02
BR9807577A (pt) 2001-08-07
LV12438B (en) 2000-09-20
BG103740A (en) 2000-05-31
MD990262A (en) 2000-06-30
HUP0100737A3 (en) 2002-07-29
LT99114A (lt) 2001-01-25
CA2281710A1 (en) 1999-07-01
LV12438A (en) 2000-03-20
LT4801B (lt) 2001-06-25
HUP0100737A2 (hu) 2001-09-28

Similar Documents

Publication Publication Date Title
NO993979L (no) FremgangsmÕte for Õ forhindre og forsinke starten pÕ Alzheimer's sykdom og sammensetning derfor
IL130931A0 (en) Small molecules useful in the treatment of inflammatory disease
PT1213015E (pt) Composicao farmaceutica oral com libertacao retardada de inibidores da bomba de protoes
DK1165537T3 (da) Hydroxymatairesinol til forebyggelse af cancer
BE2015C026I2 (en) 2-phenyl-1-[-(2-aminoethoxy)-benzyl -indole in combination with estrogens
BR9713866A (pt) Composição farmacéutica
DE68912237T2 (de) Dampfsensitive Zusammensetzung sowie diese enthaltende sterilisierungsanzeigende Zusammensetzung.
NO971206D0 (no) Forlenget-frigjöringsformulering
DK0959888T3 (da) Anvendelse af det chelerende middel clioquinol til fremstillingen af et farmaceutisk præparat til behandlingen af Alzheimer's sygdom
DK1303632T3 (da) Galactomannan-oligosaccharid og fremgangsmåde til fremstilling samt anvendelse heraf
BR9814923A (pt) Método para tratamento de doença de alzheimer
AU4830097A (en) Use of an extract of Cimicifuga
FR2818148B1 (fr) Composition,notamment cosmetique, renfermant, la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un isoflavonoide
BG102660A (en) Combined pharmaceutical preparation of lhrh-analogues and antiesterogens for the treatment of gynaecological disorders
AR030140A1 (es) Composiciones derivadas de la 2-piridinamina y metodos relacionados
BR0113165A (pt) Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados
IL143516A0 (en) COMPOUNDS AND METHODS FOR MODULATING ACTIVATION OF NF-k-B
WO2000030425A3 (en) Method of using pon-1 to decrease atheroma formation
NO985695L (no) Formulering og fremgangsmÕte for Õ behandle kongestiv hjerteinfarkt
DE29511436U1 (de) Sitzmöbel, sowie Bausatz hierfür
MX9302272A (es) Retinoides solubles en agua.
NO981320L (no) Oral anvendelse av (+)-O-demetyltramadol som smertemiddel
ATE232724T1 (de) Inhibitor von stickstoffmonoxid (no) synthase zur verhütung von typ ii diabetes
WO2001070093A3 (en) Agents and methods for the prevention of initial onset of cancers, the treatment of cancers, and the recurrence of existing cancers
FR2718965B1 (fr) Nouvelle application thérapeutique de la spiramycine.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application